Pacira (PCRX) Reports Q2 Earnings: What Key Metrics Have to Say

Core Insights - Pacira's stock has declined by 28.5% over the past month, while the Zacks S&P 500 composite has increased by 0.1%, indicating underperformance relative to the broader market [1] - The company reported revenue of $178.02 million for the quarter ended June 2024, marking a year-over-year increase of 5.1% and exceeding the Zacks Consensus Estimate by 2.72% [2] - Earnings per share (EPS) for the same quarter was $0.89, up from $0.78 a year ago, representing a surprise of 21.92% over the consensus estimate of $0.73 [2] Revenue Breakdown - Net product sales for iovera were $5.67 million, surpassing the average estimate of $5.37 million by 29.4% year-over-year [5] - ZILRETTA generated $30.71 million in net product sales, slightly above the estimated $30.11 million, reflecting a 4.9% increase compared to the previous year [5] - EXPAREL's net product sales were reported at $136.85 million, exceeding the average estimate of $135.93 million, with a year-over-year change of 1.3% [5] - Royalty revenue reached $1.64 million, significantly higher than the estimated $0.60 million [5] - Total net product sales amounted to $176.39 million, compared to the average estimate of $172.90 million, representing a year-over-year increase of 4.1% [5] - Bupivacaine liposome injectable suspension saw net product sales of $3.15 million, far exceeding the average estimate of $1.39 million, with a remarkable year-over-year change of 353.8% [5]